HAE (Haemonetics Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by HAE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-28 | Ellen M Zane | Director | A | — | — |
| 2026-07-28 | Lloyd Emerson Johnson | Director | A | — | — |
| 2026-07-28 | Martin D Madaus | Director | A | — | — |
| 2026-07-28 | Diane M Bryant | Director | A | — | — |
| 2026-07-28 | ROBERT E ABERNATHY | Director | A | — | — |
| 2026-07-28 | MICHAEL J COYLE | Director | A | — | — |
| 2026-07-28 | MARK W KROLL | Director | A | — | — |
| 2026-07-28 | Claire Pomeroy | Director | A | — | — |
| 2026-06-08 | Farris Maryanne Maunsell | VP, Chief Accounting Officer | F | — | — |
| 2026-06-08 | Laurie A. Miller | SVP, Human Resources | F | — | — |
| 2026-05-19 | Christopher Simon | President & CEO | MIXED | — | — |
| 2026-05-19 | Laurie A. Miller | SVP, Human Resources | MIXED | — | — |
| 2026-05-19 | Roy Galvin | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-05-19 | Farris Maryanne Maunsell | VP, Chief Accounting Officer | MIXED | — | — |
| 2026-05-19 | James DArecca | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-05-19 | Frank Chan | EVP, Chief Operating Officer | MIXED | — | — |
| 2026-05-19 | Michelle L Basil | EVP and General Counsel | MIXED | — | — |
| 2026-05-05 | James DArecca | EVP, Chief Financial Officer | F | — | — |
| 2025-11-12 | MARK W KROLL | Director | Buy | — | — |
| 2025-11-03 | Roy Galvin | EVP, Chief Commercial Officer | F | — | — |
| 2025-09-24 | Laurie A. Miller | SVP, Human Resources | F | — | — |
| 2025-07-25 | ROBERT E ABERNATHY | Director | A | — | — |
| 2025-07-25 | Diane M Bryant | Director | A | — | — |
| 2025-07-25 | MICHAEL J COYLE | Director | A | — | — |
| 2025-07-25 | Charles J Dockendorff | Director | A | — | — |
| 2025-07-25 | Lloyd Emerson Johnson | Director | A | — | — |
| 2025-07-25 | MARK W KROLL | Director | A | — | — |
| 2025-07-25 | Claire Pomeroy | Director | A | — | — |
| 2025-07-25 | Ellen M Zane | Director | A | — | — |
| 2025-06-13 | Michelle L Basil | EVP and General Counsel | A | — | — |
| 2025-06-13 | Roy Galvin | EVP, Chief Commercial Officer | A | — | — |
| 2025-06-09 | Farris Maryanne Maunsell | VP, Chief Accounting Officer | A | — | — |
| 2025-06-09 | Laurie A. Miller | SVP, Human Resources | A | — | — |
| 2025-06-03 | Michelle L Basil | EVP and General Counsel | MIXED | — | — |
| 2025-06-03 | James DArecca | EVP, Chief Financial Officer | MIXED | — | — |
| 2025-06-03 | Laurie A. Miller | SVP, Human Resources | MIXED | — | — |
| 2025-06-03 | Christopher Simon | President & CEO | MIXED | — | — |
| 2025-05-20 | Christopher Simon | President & CEO | A | — | — |
| 2025-05-20 | James DArecca | EVP, Chief Financial Officer | A | — | — |
| 2025-05-20 | Michelle L Basil | EVP and General Counsel | A | — | — |
| 2025-05-20 | Roy Galvin | President, Global Plasma & BC | A | — | — |
| 2025-05-20 | Frank Chan | EVP, Chief Operating Officer | A | — | — |
| 2025-05-20 | Laurie A. Miller | SVP, Human Resources | A | — | — |
| 2025-05-20 | Farris Maryanne Maunsell | VP, Chief Accounting Officer | A | — | — |
| 2025-05-19 | Christopher Simon | President & CEO | F | — | — |
| 2025-05-19 | Laurie A. Miller | SVP, Human Resources | F | — | — |
| 2025-05-19 | Roy Galvin | President, Global Plasma & BC | F | — | — |
| 2025-05-19 | Farris Maryanne Maunsell | VP, Chief Accounting Officer | F | — | — |
| 2025-05-19 | James DArecca | EVP, Chief Financial Officer | F | — | — |
| 2025-05-19 | Michelle L Basil | EVP and General Counsel | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President & CEO | 366,360 | — |
| — | President & CEO | 153,609 | — |
| — | EVP and General Counsel | 68,829 | — |
| — | President, Global Plasma | 64,596 | — |
| — | CFO & EVP Business Development | 56,743 | — |
| — | Director | 54,957 | — |
| — | EVP, Chief Financial Officer | 54,444 | — |
| — | EVP, Chief Financial Officer | 52,958 | — |
| — | EVP and Chief Legal Officer | 48,166 | — |
| — | SVP, Human Resources | 40,987 | — |
| — | EVP, Chief Commercial Officer | 39,882 | — |
| — | EVP, Global Manufacturing | 35,450 | — |
| — | Director | 32,050 | — |
| — | Vice President, Operations | 31,698 | — |
| — | Chief Science and Technology | 30,507 | — |
| — | Director | 27,519 | — |
| — | Director | 27,295 | — |
| — | Director | 25,041 | — |
| — | President, Global Markets | 24,884 | — |
| — | VP, Manufacturing | 24,376 | — |
| — | President, Global Markets | 23,318 | — |
| — | Director | 21,911 | — |
| — | EVP, Chief Technology Officer | 21,410 | — |
| — | Director | 21,340 | — |
| — | Chairman of the Board | 21,160 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HAE quote page; the site-wide leaderboard is on the insider transactions hub.